Theophylline as 'add-on' therapy to cetirizine in patients with chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled pilot study

International Archives of Allergy and Immunology

Volumn 139, Issue 3, 2006, Pages 258-264

  Kalogeromitros, Dimitrios ^a   Kempuraj, Duraisamy ^c   Katsarou Katsari, Alexandra ^b   Makris, Michael ^a   Gregoriou, Stamatis ^b   Papaliodis, Dean ^c   Theoharides, Theoharis C ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ANDREAS SYGROS HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cetirizine; Inflammation; Phosphodiesterase; Theophylline; Urticaria

Indexed keywords

CETIRIZINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE; PHOSPHODIESTERASE INHIBITOR; THEOPHYLLINE;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; CHRONIC URTICARIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; DRUG SPECIFICITY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; CETIRIZINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PILOT PROJECTS; THEOPHYLLINE; URTICARIA;

EID: 33344465329     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091171     Document Type: Article

References (38)

1. Kaplan AP: Urticaria and angioedema: in Adkinson NF Jr, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER (eds): Allergy: Principles and Practice. Philadelphia, Mosby, 2003, pp 1537-1558.
2. Beltrani VS: An overview of chronic urticaria. Clin Rev Allergy Immunol 2002;23:1147-1169.
3. Greaves M: Chronic urticaria. J Allergy Clin Immunol 2000;105:664-672.
4. Grattan CEH, Hamon CGB, Cowan MA, Leeming RJ: Preliminary identification of a low molecular weight serological mediator in chronic idiopathic urticaria. Br J Dermatol 1988;119:179-184.
5. Hide M, Francis DM, Grattan CEH, Hakimi J, Kochan JP, Greaves MW: Autoantibodies against the high affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993;328:1599-1604.
6. Ying S, Robinson DS, Meng Q, Barata LT, McEuen AR, Buckley MG: C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and eotaxin-2 and MCP-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (MCP-3 and RANTES). J Immunol 1999;163:3976-3984.
7. Kozel MM, Sabroe RA: Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004;64:2515-1536.
8. Kaplan AP: Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002;346: 175-179.
9. Asero R, Tedeschi A, Lorini M: Leukotriene receptor antagonists in chronic urticaria. Allergy 2001;56:456-457.
10. Biondi MG: Theophylline in the therapy of urticaria. G Ital Dermatol Venereol 1986;121: 71-72.
11. Lim S, Tomita K, Carramori G, Jatakanon A, Oliver B, Keller A, Adcock I, Chung KF, Barnes PJ: Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med 2001;164:273-276.
12. Culpitt SV, de Matos C, Russell RE, Donnelly LE, Rogers DF, Barnes PJ: Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:1371-1376.
13. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ: Immunomodulation by theophylline in asthma: demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995;151:1907-1914.
14. Weldon D: When your patients are itching to see you: not all hives are urticaria. Allergy Asthma Proc 2005;26:1-7.
15. Serratrice J, de Roux-Derratrice C, Ene N, Granel B, Disdier P, Weiller PJ: Urticarial vasculitis revealing relapsing polychondritis. Eur J Intern Med 2005;16:207-208.
16. Sabroe RA, Fiebiger E, Francis DM, Maurer D, Seed PT, Gratten CE, Black AK, Stingl G, Greaves MW, Barr RM: Classification of anti-FcεRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol 2002; 110:492-499.
17. Brostoff J, Fitzharris P, Dunmore C, Theron M, Blondin P: Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. Allergy 1996;51:320-325.
18. Finn AF Jr, Kaplan AP, Fretwell R, Qu R, Long J: A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999;104:1071-1078.
19. Parsad D, Pandhi R, Juneja A: Stanozolol in chronic idiopathic urticaria: a double blind, placebo-controlled trial. J Dermatol 2001;28: 299-302.
20. Chan SC, Hanifin JM: Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. J Lab Clin Med 1993;121:44-51.
21. Spina D, Landells LJ, Page CP: The role of theophylline and phosphodiesterase-4 isoenzyme inhibitors as anti-inflammatory drugs. Clin Exp Allergy 1998;3:24-34.
22. Crocker IC, Townley RG, Khan MM: Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. Immunopharmacology 1996;31: 223-235.
23. Draheim R, Egerland U, Rundfeldt C: Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4- fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations. J Pharmacol Exp Ther 2004; 308:555-563.
24. Bissonnette E, Befus AD: Anti-inflammatory effect of β2-agonists: inhibition of TNF-α release from human mast cells. J Allergy Clin Immunol 1997;100:825-831.
25. Church MK, Hiroi J: Inhibition of IgE-dependent histamine release from dispersed lung mast cells by anti-allergic drugs and salbutamol. Br J Pharmacol 1987;90:421-429.
26. Greaves MW, Wall PD: Pathophysiology of itching. Lancet 1996;348:938-940.
27. Takano N, Arai I, Hashimoto Y, Karachi M: Evaluation of antipruritic effects of several agents on scratching behavior by NC/Nga mice. Eur J Pharmacol 2004;495:159-165.
28. Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer G, Skov PS, Luger TA, Schmelz M: Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003;23:6176-6180.
29. Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, Trevisani M, Hollenberg MD, Wallace JL, Caughey GH, Mitchell SE, Williams LM, Geppetti P, Mayer EA, Bunnett NW: Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000;6:151-158.
30. Katsarou-Katsari A, Filippou A, Theoharides TC: Effect of stress and other psychological factors on the pathophysiology and treatment of dermatoses. Int J Immunopathol Pharmacol 1999;12:7-11.
31. Nikoletta P, Kalogeromitros D, Staurianeeas NG, Tiblalexi D, Theoharides TC: Corticotropin-releasing hormone receptor and histidine decarboxylase expression in chronic urticaria. J Invest Dermatol 2005;125:432-455.
32. Singh LK, Pang X, Alexacos N, Letourneau R, Theoharides TC: Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin and substance P: a link to neurogenic skin disorders. Brain Behav Immun 1999;13:225-239.
33. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E: Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 1998;139:403-413.
34. Paus R, Theoharides TC, Arck PC: Neuroimmunoendocrine circuitry of the 'brain-skin connection'. Trends Immunol, in press.
35. Cao J, Papadopoulou N, Kempuraj D, Boucher W, Sugimoto K, Cetrulo CL, Theoharides TC: Human mast cell express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 2005; 174:7665-7675.
36. Kempuraj D, Huang M, Kandere K, Boucher W, Letoumeau R, Jeudy S, Fitzerald K, Spear K, Athanasiou A, Theoharides TC: Azelastine is more potent than olopatadine in inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells. Ann Allergy Asthma Immunol 2002;88: 501-506.
37. Martinez-Cocera C, De Molina M, Marti-Guadano E, Pola J, Conde J, Borja J, Perez I, Arnaiz E, Izquierdo I, Spanish Rupatadine Study Group: Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J Investig Allergol Clin Immunol 2005;15:22-29.
38. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P: Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 2004;25: 563-568.